Orthopedic Consolidation Continues: IsoTis Deal Unites Bone Graft Developers
This article was originally published in The Gray Sheet
IsoTis will continue to develop its Allox allogenic growth factor spray for chronic wound treatment, while directing the majority of its R&D at osteobiologics
You may also be interested in...
Pre-merger licensing pact allows firms to move ahead with platform integration, giving IsoTis access to GenSci technology related to its demineralized bone matrix reverse-phase medium (RPM) carrier system. IsoTis will combine the RPM carrier system with its lead OsSatura synthetic bone substitute technology for dental and maxillofacial reconstruction. A June 3 merger deal is expected to close this fall (1"The Gray Sheet" June 9, 2003, p. 26)...
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.